Patents Examined by Amy Bowman
  • Patent number: 9920317
    Abstract: This invention relates to polycomb-associated long non-coding RNAs (lncRNAs), libraries and fragments of those ncRNAs, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: March 20, 2018
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Jing Zhao, Kavitha Sarma, Mark Borowsky, Toshiro Kendrick Ohsumi
  • Patent number: 9903000
    Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: February 27, 2018
    Assignee: Andes Biotechnologies Global, Inc.
    Inventors: Luis O. Burzio, Jaime E. Villegas, Veronica A. Burzio
  • Patent number: 9885033
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 6, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, James Angstman, Jeffry D. Sander, Morgan Maeder, Shengdar Tsai
  • Patent number: 9885057
    Abstract: The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: February 6, 2018
    Assignee: University of Massachusetts
    Inventors: Terence Flotte, Christian Mueller, Phillip D. Zamore
  • Patent number: 9879265
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Patent number: 9879255
    Abstract: The present invention provides oligonucleotides that inhibit the binding of miR-27a to VE-cadherin mRNA, particularly in the form of blockmirs. The invention also provides compositions comprising such oligonucleotides and methods of use of such oligonucleotides to modulate the activity of VE-cadherin, inhibit or reduce vascular permeability, treat or prevent a vascular permeability-associated disease or condition, inhibit tumor growth, treat ischaemic injury, enhance recovery from ischaemic injury, treat surgical wounds and/or promotes post-operative recovery, and promote or induce angiogenesis.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: January 30, 2018
    Assignee: University of Newcastle Upon Tyne
    Inventors: Jennifer Gamble, Mathew Vadas, Thorleif Moller
  • Patent number: 9868950
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: January 16, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • Patent number: 9862944
    Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Inventors: Luis O. Burzio Eriz, Veronica A. Burzio Menendez, Jaime E. Villegas Olavarria
  • Patent number: 9855314
    Abstract: The present invention relates to compositions and methods comprising administering gene modifiers for treating ocular disease.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 2, 2018
    Assignee: The Schepens Eye Research Insititute, Inc.
    Inventor: Neena B. Haider
  • Patent number: 9855273
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 2, 2018
    Assignee: Children's Hospital Medical Center
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen
  • Patent number: 9856478
    Abstract: The present invention features methods for preventing and treating three related diseases, diet-induced obesity, metabolic syndrome, and atherosclerosis, alone or in combination by inhibiting Acyl-CoA:Cholesterol Acyltransferase 1 (ACATI) activity or expression in myeloid cells.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: January 2, 2018
    Inventors: Ta-Yuan Chang, Catherine C. Y. Chang, Li-Hao Huang, Elaina Melton, Paul Sohn
  • Patent number: 9845472
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: December 19, 2017
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • Patent number: 9840710
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 12, 2017
    Assignees: Rosalind Franklin University of Medicine and Science, The McLean Hospital Corporation
    Inventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
  • Patent number: 9820987
    Abstract: The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: November 21, 2017
    Assignee: Bionsil S.R.L. in Liquidazione
    Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
  • Patent number: 9790507
    Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, a composition comprising an aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly solid tumors.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: October 17, 2017
    Inventors: Günter Mayer, Ursula Maria Katia Schöler, Mohammad Seyed Taghdisi Heidarian
  • Patent number: 9790494
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: October 17, 2017
    Assignee: Translate Bio MA, Inc.
    Inventors: Eugen Uhlmann, Romesh Subramanian, Arthur M. Krieg
  • Patent number: 9783806
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: October 10, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin Maier, Klaus Charisse
  • Patent number: 9782522
    Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: October 10, 2017
    Assignee: Yale University
    Inventors: Christopher Breuer, Tarek Fahmy, Michael Simons, Pei-Yu Chen, Daniel Rowe Duncan, Joseph Patterson
  • Patent number: 9777278
    Abstract: Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: October 3, 2017
    Inventors: Dong Liang, David Sweedler, Kunyuan Cui
  • Patent number: 9777279
    Abstract: Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout siRNA, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of T cells by selectively targeting memory T cells with the nanoparticles, which deliver their siRNA cargo into the cytosol of the TM cell thus reducing ion channel expression and decreasing Ca2+ influx.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 3, 2017
    Assignees: University of Cincinnati, North Carolina Agricultural and Technical State University
    Inventors: Laura Conforti, Yeoheung Yun